Axsome Therapeutics Research Development Over Time
| AXSM Stock | USD 180.75 4.79 2.58% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Axsome Therapeutics Performance and Axsome Therapeutics Correlation. Will Pharmaceuticals sector continue expanding? Could Axsome diversify its offerings? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Axsome Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.67) | Revenue Per Share | Quarterly Revenue Growth 0.632 | Return On Assets | Return On Equity |
Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.
Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Research Development Analysis
Compare Axsome Therapeutics and related stocks such as Nuvalent, Metsera Common Stock, and Abivax SA American Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NUVL | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 9.7 M | 15.4 M | 35.6 M | 63.7 M | 113.2 M | 217.8 M | 250.4 M | 263 M |
| ABVX | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 15.5 M | 10.8 M | 15.9 M | 29 M | 34.5 M | 47.8 M | 48.7 M | 103.2 M | 146.5 M | 168.5 M | 176.9 M |
| CYTK | 10.4 M | 37.2 M | 35.6 M | 49.5 M | 44.4 M | 46.4 M | 59.9 M | 90.3 M | 89.1 M | 86.1 M | 97 M | 159.9 M | 240.8 M | 330.1 M | 339.4 M | 390.3 M | 409.8 M |
| RYTM | 15.7 M | 15.7 M | 15.7 M | 18 M | 5.3 M | 7.1 M | 19.6 M | 22.9 M | 50.3 M | 109.5 M | 90.5 M | 104.1 M | 108.6 M | 135 M | 238 M | 273.7 M | 287.3 M |
| ARWR | 3.4 K | 5.4 M | 8.7 M | 23.1 M | 57.4 M | 62.1 M | 50.9 M | 53 M | 81 M | 128.9 M | 206.3 M | 297.3 M | 353.2 M | 505.9 M | 607.2 M | 698.2 M | 733.1 M |
| CRSP | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 12.6 M | 42.2 M | 69.8 M | 113.8 M | 179.4 M | 221.4 M | 438.6 M | 461.6 M | 387.3 M | 320.7 M | 368.8 M | 224.9 M |
| PCVX | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 30.1 M | 45.6 M | 73.6 M | 78.4 M | 169.5 M | 332.3 M | 476.6 M | 548.1 M | 575.5 M |
| JAZZ | 45.8 M | 14.1 M | 20.5 M | 46.6 M | 85.2 M | 135.3 M | 162.3 M | 198.4 M | 226.6 M | 299.7 M | 335.4 M | 505.7 M | 590.5 M | 849.7 M | 884 M | 1 B | 1.1 B |
Axsome Therapeutics and related stocks such as Nuvalent, Metsera Common Stock, and Abivax SA American Research Development description
My Equities
My Current Equities and Potential Positions
| Axsome Therapeutics | AXSM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | One World Trade |
| Exchange | NASDAQ Exchange |
USD 180.75
Check out Axsome Therapeutics Performance and Axsome Therapeutics Correlation. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Axsome Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.